Vanda Gets a Buy Rating from Jefferies

By Ryan Adsit

In a report released today, Matthew Andrews from Jefferies reiterated a Buy rating on Vanda (NASDAQ: VNDA), with a price target of $20. The company’s shares opened today at $15.50.

According to, Andrews is a 5-star analyst with an average return of 28.9% and a 47.2% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aevi Genomic Medicine Inc, and Spectrum Pharmaceuticals.

Vanda has an analyst consensus of Moderate Buy, with a price target consensus of $20.

The company has a one-year high of $18.99 and a one-year low of $11.90. Currently, Vanda has an average volume of 505.6K.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.